Cargando…

Metabolic disorders induced by PNPLA3 and TM6SF2 gene variants affect chronic kidney disease in patients infected with non-genotype 3 hepatitis C virus

BACKGROUND: Patients with chronic hepatitis C virus (HCV) infections differ in their risk for metabolic disorders and chronic kidney disease (CKD). The aim of this study was to investigate the effect of metabolic disorders induced by genetic factors on CKD in HCV-infected patients. METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jia, Qi, Wenqian, Wang, Song, Zhang, Yonggui, Wang, Xu, Sun, Derong, Xu, Yanhui, Shi, Jingyi, Duan, Honglei, Zhang, Qian, Wang, Hongguang, Wang, Jiangbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316563/ https://www.ncbi.nlm.nih.gov/pubmed/37400794 http://dx.doi.org/10.1186/s12944-023-01858-4

Ejemplares similares

Identification of deleterious rare variants in MTTP, PNPLA3, and TM6SF2 in Japanese males and association studies with NAFLD
por: Boonvisut, Supichaya, et al.
Publicado: (2017)

PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease
por: Lisboa, Quelson Coelho, et al.
Publicado: (2020)

Two genetic variants in the SRD5A2 gene are found to be associated with sex differences in the disease characteristics of patients with chronic hepatitis B virus infection
por: Duan, Honglei, et al.
Publicado: (2023)

Genetic Polymorphism of CYP27B1-1260 as Associated With Impaired Fasting Glucose in Patients With Chronic Hepatitis C Undergoing Antiviral Therapy
por: Sun, Derong, et al.
Publicado: (2016)

PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study
por: Rauff, Bisma, et al.
Publicado: (2022)

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist
por: Guzman, Cristina B., et al.
Publicado: (2018)

The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C
por: Oliveira, Arthur Ivan N., et al.
Publicado: (2021)

Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population
por: Wang, Xiaoliang, et al.
Publicado: (2016)

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects
por: Sliz, Eeva, et al.
Publicado: (2018)

Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer
por: Sunami, Yoshiaki, et al.
Publicado: (2021)

NOTCH3 rs1043996 Polymorphism Is Associated with the Occurrence of Alcoholic Liver Cirrhosis Independently of PNPLA3 and TM6SF2 Polymorphisms
por: Bainrauch, Ana, et al.
Publicado: (2021)

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
por: Longo, Miriam, et al.
Publicado: (2021)

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan
por: Akuta, Norio, et al.
Publicado: (2016)

The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism
por: Chen, Lizhen, et al.
Publicado: (2017)

Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease
por: Paternostro, Rafael, et al.
Publicado: (2021)

Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study
por: Köpp, Julia, et al.
Publicado: (2016)

Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis
por: Gabriel-Medina, Pablo, et al.
Publicado: (2022)

The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients
por: Liu, Zhenhua, et al.
Publicado: (2017)

PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial
por: Dallio, Marcello, et al.
Publicado: (2021)

Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease
por: Wu, Jian-Ting, et al.
Publicado: (2020)

PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction
por: Gou, Yusong, et al.
Publicado: (2023)

PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC
por: Kruk, Beata, et al.
Publicado: (2018)

Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases
por: Xiang, Hongjiao, et al.
Publicado: (2021)

Association of PNPLA3 (rs738409) & TM6SF2 (rs58542926) and ATG16L1 (rs2241880) genetic variants with susceptibility to hepatocellular carcinoma in a group of Egyptian patients with HCV-induced liver cirrhosis
por: Mohamed Fteah, Asmaa, et al.
Publicado: (2023)

Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
por: Smagris, Eriks, et al.
Publicado: (2015)

PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
por: Rembeck, Karolina, et al.
Publicado: (2012)

TGF-Β1, PNPLA3 Genetic Variants and the Risk of Hepatic Fibrosis: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance
por: Rahim, Nur Syafiqah, et al.
Publicado: (2023)

PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice
por: Wang, Yang, et al.
Publicado: (2019)

Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
por: BasuRay, Soumik, et al.
Publicado: (2019)

Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma
por: Chen, Zhouxun, et al.
Publicado: (2011)

TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis
por: Basyte-Bacevice, Viktorija, et al.
Publicado: (2019)

PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients
por: Huang, Chung-Feng, et al.
Publicado: (2015)

TM4SF1 promotes esophageal squamous cell carcinoma metastasis by interacting with integrin α6
por: Hou, Sicong, et al.
Publicado: (2022)

The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant
por: Zhang, Xiaoyu, et al.
Publicado: (2018)

Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis
por: Zhu, Wenzhen, et al.
Publicado: (2022)

Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant
por: Leníček, Martin, et al.
Publicado: (2021)

No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV
por: Nakamura, Masato, et al.
Publicado: (2013)

TM4SF1 Promotes Metastasis of Pancreatic Cancer via Regulating the Expression of DDR1
por: Yang, Jia-chun, et al.
Publicado: (2017)

PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_difnuio8b086msja2mpfegl6ki